![](data:image/png;base64,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)
48 Alvarez-Sarmiento, Jessica y col.
29 US Food And Drug Administra-
tion (2016). Kovanaze. Available from:
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.
cfm?event=overview.process&ApplNo=208032 [Accessed
on 23 September 2019].
30 Capetillo J, Drum M, Reader A, Fowler S, Nusstein J, Beck
M. Anesthetic Efficacy of Intranasal 3 % Tetracaine plus
0.05 % Oxymetazoline (Kovanaze) in Maxillary Teeth. J
Endod. 2019; 45: 257–62.
31 Kumar A, Raj J. Knowledge, attitude, and practices regar-
ding the use of nasal spray anesthesia by dental practitio-
ners. Drug invent today. 2018; 10: 2023-28.
32 Hersh E, Saraghi M, Moore P. Intranasal tetracaine and
oxymetazoline: a newly approved drug formulation that
provides maxillary dental anesthesia without needles. Curr
Med Res Opin. 2016; 32: 1919–25.
33 Ciancio S, Hutcheson M, Ayoub F, Pantera E, Pantera C,
Garlapo D, et al. Safety and efficacy of a novel nasal spray
for maxillary dental anesthesia. J Dent Res. 2013; 92: 43S-
8S.
34 Hersh E, Saraghi M, Moore P. Two Recent Advances in
Local Anesthesia: Intranasal Tetracaine/Oxymetazoline and
Liposomal Bupivacaine. Curr Oral Health Rep. 2017; 4:
189–196.
35 Giannakopoulos H, Levin L, Chou J, Cacek A, Hutcheson
M, Secreto S, et al. The cardiovascular effects and phar-
macokinetics of intranasal tetracaine plus oxymetazoline:
preliminary findings. J Am Dent Assoc. 2012; 143: 872–80.
36 Higgins T, Hwang P, Kingdom T, Orlandi R, Stammberger
H, Han J. Systematic Review of Topical Vasoconstrictors
in Endoscopic Sinus Surgery. Laryngoscope. 2011; 121:
422–32.
37 Hersh E, Pinto A, Saraghi M, Saleh N, Pulaski L, Gordon
S, et al. Double-masked, randomized, placebo-controlled
study to evaluate the efficacy and tolerability of intrana-
sal K305 (3 % tetracaine plus 0.05 % oxymetazoline) in
anesthetizing maxillary teeth. J Am Dent Assoc. 2016; 147:
278–87.
38 Cacek A, Gobburu J, Gopalakrishnan M. Population Phar-
macokinetics of an Intranasally Administered Combination
of Oxymetazoline and Tetracaine in Healthy Volunteers. J
Clin Pharmacol. 2017; 57: 247–54.
39 Misra A, Shahiwala A. Novel drug delivery technologies in-
novative strategies for drug re-positioning, 1st ed. Springer
Singapore, 2019.
40 Laube B, Sharpless G, Vikani A, Harrand V, Zinreich S,
Sedberry K, et al. Intranasal Deposition of AccusprayTM
Aerosol in Anatomically Correct Models of 2-, 5-, and 12-
Year-Old Children. J Aerosol Med Pulm Drug Deliv. 2015;
28: 320–33.
41 Evans G, Yiming L. A phase 3, multi-center, randomized,
double-blind, parallel-groups clinical trial comparing the ef-
ficacy and safety of intranasally administered K-305 to pla-
cebo for anesthetizing maxillary teeth in pediatric patients.
2016 [citado 2 de abril de 2020]. Available from:URL:
https://www.fda.gov/downloads/Drugs/Development
ApprovalProcess/DevelopmentResources/UCM513665.pdf
42 Madurantakam P. Kovanaze Vs. Articaine in Achieving
Pulpal Anesthesia of Maxillary Teeth - Pediatric. 2019
[citado 2 de abril de 2020]. Available from: URL:
https://clinicaltrials.gov/ct2/show/NCT03962634
43 Szmuk P, Szmuk E, Ezri T. Use of needle-free injection sys-
tems to alleviate needle phobia and pain at injection. Expert
Rev Pharmacoenomics Outcomes Res. 2005; 5: 467–77.
44 Milani A, Froughreyhani M, Rahimi S, Zand V, Jafarabadi
Ma. Volume of Anesthetic Agents and IANB Success: A
Systematic Review. Anesth Prog. 2018; 65: 16–23.
45 Abazarpoor R, Parirokh M, Nakhaee N, Abbott P. A Compa-
rison of Different Volumes of Articaine for Inferior Alveolar
Nerve Block for Molar Teeth with Symptomatic Irreversible
Pulpitis. J Endod. 2015; 41: 1408–11.
46 Mikesell A, Drum M, Reader A, Beck M. Anesthetic Effi-
cacy of 1.8 mL and 3.6 mL of 2 % Lidocaine with 1:100,000
Epinephrine for Maxillary Infiltrations. J Endod. 2008; 34:
121–5.
47 Aggarwal V, Singla M, Miglani S, Kohli S, Sharma V,
Bhasin S. Does the volume of supplemental intraligamen-
tary injections affect the anaesthetic success rate after a
failed primary inferior alveolar nerve block? A randomized-
double blind clinical trial. Int Endod J. 2018; 51: 5–11.
48 Brunetto P, Ranali J, Ambrosano G, De Oliveira P, Groppo
F, Meechan J, et al. Anesthetic efficacy of 3 volumes of lido-
caine with epinephrine in maxillary infiltration anesthesia.
Anesth Prog. 2008; 55: 29–34.
49 Singla M, Subbiya A, Aggarwal V, Vivekanandhan P, Yadav
S, Yadav H, et al. Comparison of the anaesthetic efficacy
of different volumes of 4 % articaine (1.8 and 3.6 mL) as
supplemental buccal infiltration after failed inferior alveolar
nerve block. Int Endod J. 2015; 48: 103–8.
50 Pfeil L, Drum M, Reader A, Gilles J, Nusstein J. Anesthe-
tic Efficacy of 1.8 Milliliters and 3.6 Milliliters of 2 %
Lidocaine with 1:100,000 Epinephrine for Posterior Supe-
rior Alveolar VREELAND DL, READER A, BECK M,
MEYERS W, WEAVER J. An evaluation of volumes and
concentrations of lidocaine in human inferior alveolar nerve
block. J Endod. 1989; 15: 6–12.
51 Vreeland D, Reader A, Beck M, Meyers W, Weaver J. An
evaluation of volumes and concentrations of lidocaine in
human inferior alveolar nerve block. J Endod. 1989; 15:
6–12.
52 Nusstein J, Reader A, Beck F. Anesthetic efficacy of dif-
ferent volumes of lidocaine with epinephrine for inferior
alveolar nerve blocks. Gen Dent. 2002; 50: 372–5.
53 Parirokh M, Satvati S, Sharifi R, Rekabi A, Gorjestani H,
Nakhaee N, et al. Efficacy of combining a buccal infiltration
with an inferior alveolar nerve block for mandibular molars
with irreversible pulpitis. Oral Surg, Oral Med, Oral Pathol,
Oral Radiol, and Endod. 2010; 109: 468–73.
Revista OACTIVA UC Cuenca. Vol. 6, No. 1, Enero-Abril, 2021